Xenon Pharmaceuticals Inc
Suletud
SektorTervishoid
66.78 0.45
Ülevaade
Aktsiahinna muutus
24h
Min
65.75
Max
68.71
Sissetulek | 3M -102M |
|---|---|
Aktsiakasum | -1.17 |
Töötajad | 358 |
EBITDA | -7.6M -112M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +11% upside |
Järgmine tulemuste avaldamine | 10. aug 2026 |
|---|
Turukapital | 1.1B 6.7B |
|---|---|
Eelmine avamishind | 66.33 |
Eelmine sulgemishind | 66.78 |
Xenon Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Xenon Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
11% tõus
12 kuu keskmine prognoos
Keskmine 75.77 USD 11%
Kõrge 86 USD
Madal 63 USD
Põhineb 11 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
